• LinkedIn
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Youtube
  • Rss
  • Home
  • Events
  • Careers at CAPTIS
  • Log In / Sign In ▼
    • Log In with LinkedIn
    • Register w/out LinkedIn
    • Login w/out LinkedIn
    • Reset Lost Password
  • 🔒 MEMBER AREA ▼
    • View your profile
    • Edit your profile
    • Log out
       ☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS Executive Search
  • CAPTIS
  • You are a Business
    • Executive Search
    • Our Commitments
    • Other Services
    • Our Locations
    • About Us
    • Key Values
  • You are a Healthcare Executive
    • Dealing with CAPTIS
    • Candidate Contact Form
    • Login with LinkedIn
    • Create an Account
    • Log in (Existing Account)
    • WW Trade Shows
      • Medical & Pharmaceutical
      • Orthopedics
      • Spine
      • Cardiovascular
      • Diagnostics
      • Wound Care
      • Plastic & Aesthetic Surgery
      • Surgery
      • Trauma
      • Pediatric Care
    • Industry News
      • News
      • Wall Street Beat
      • Business/Financial News
      • Clinical Trials
      • Musculoskeletal News Roundup
      • Cardiovascular
      • M&A Activity
      • Food & Drug Administration (FDA)
      • Wound Care
      • Practice Management
  • CAPTIS Magazine
    • Healthcare News
    • @CaptisCorp Twitter Timeline
    • Healthcare Events
    • CAPTIS LinkedIn Timeline
    • Articles ➜
      • Recruiting
      • Personal Development
      • News
  • Make an Inquiry
  • Contact Us
    • General Contact Form
    • Healthcare Executive Contact
    • Apply for a position at CAPTIS
    • Call 1 800 445 1839
      (Cell/Mobile US & Canada Toll Free, or Skype)
    • Call +41 22 518 2100
      (Cell/Mobile Swiss Landline Switchboard, or Skype)
  • Search
  • Menu Menu

CAPTIS – Executive Search & Management Consulting

Captare. Aestimare. Eligere. Succedere.

You are a Business

You are an Executive

Want to work at CAPTIS

Learn about our services

 

 

Executive Search
Submit an inquiry

Create and/or update

your confidential profile

 

Executive’s General Information
Create an account & Add your profile

Go to our Careers page

 

 

CAPTIS Careers

Recent Healthcare News:

10/28/2020

FDA grants priority review and EMA accepts regulatory submission for Pfizer’s abrocitinib

The FDA is expected to make a decision in April 2021. The European…
10/28/2020

GSK, Sanofi to supply 200 million doses of Covid-19 vaccine to COVAX

10/28/2020

Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease

10/28/2020

Aurinia begins voclosporin trial in kidney transplant recipients with Covid-19

10/27/2020

ANA Therapeutics starts oral niclosamide trial for Covid-19 treatment

10/27/2020

HiFiBiO completes first cohort of phase 1 study of SARS-CoV-2 neutralising antibody

10/27/2020

Moderna to supply Qatar with mRNA vaccine against Covid-19

10/27/2020

Bayer to acquire Asklepios BioPharmaceutical for up to $4bn

10/26/2020

FDA authorises restart of the COVID-19 AZD1222 vaccine US phase 3 trial

10/26/2020

Novartis’ iptacopan gets EMA’s orphan drug designation in IgAN

10/23/2020

Sirnaomics seals $105m Series D financing for RNAi therapeutics

This round of funding was co-led by existing investor Rotating…
10/22/2020

US FDA approves Gilead’s antiviral drug Veklury for treatment of Covid-19

10/22/2020

EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi

10/22/2020

Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans

10/22/2020

Novartis gets FDA orphan drug status for branaplam to treat Huntington’s disease

10/22/2020

ImmunityBio, NantKwest dose first patient in novel Covid-19 vaccine candidate trial

10/21/2020

TAGRISSO granted FDA priority review in early-stage EGFR-mutated lung cancer

10/21/2020

JSR Life Sciences to expand KBI Biopharma and Selexis’ biologics manufacturing capabilities

10/21/2020

Xeris Pharmaceuticals granted fast track designation by FDA for novel concentrated diazepam formulation for injection

10/21/2020

Astellas Pharma gets FDA fast track status for ASP036 to treat primary mitochondrial myopathies

Go to the Healthcare News

Recent news from your industry: Finance, M&A, Products, Companies and more…

Upcoming Events:

SOFCOT 2020

November 9 - November 11Palais des Congrès, Paris, France

We Suggest:

VelosBio announces first patient dosed in phase 2 trial of VLS-101 in solid tumours

0 Comments
/
10/20/2020
ROR1 is a cell-surface protein that is expressed during embryofetal…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-20 05:01:372020-10-20 05:01:38VelosBio announces first patient dosed in phase 2 trial of VLS-101 in solid tumours

Versantis receives FDA rare paediatric disease designation for VS-01 to treat urea cycle disorders

0 Comments
/
10/20/2020
UCD is a rare and life-threatening condition caused by an inherited…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-20 04:31:412020-10-20 04:31:42Versantis receives FDA rare paediatric disease designation for VS-01 to treat urea cycle disorders

Vifor Pharma, Cara Therapeutics to commercialise kidney disease drug Korsuva in US

0 Comments
/
10/20/2020
In May 2018, Cara Therapeutics and Vifor Fresenius Medical Care…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-20 02:31:112020-10-20 02:31:12Vifor Pharma, Cara Therapeutics to commercialise kidney disease drug Korsuva in US

Dren Bio announces a $60M Series A financing

0 Comments
/
10/19/2020
The round was led by SR One and Taiho Ventures, LLC , with participation…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-19 05:32:362020-10-19 05:32:36Dren Bio announces a $60M Series A financing

Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukemia

0 Comments
/
10/19/2020
Venclexta was previously granted provisional approval in this…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-19 04:31:572020-10-19 04:31:57Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukemia

Dr. Reddy’s, RDIF secure DCGI’s approval for Sputnik V vaccine trial in India

0 Comments
/
10/19/2020
The approval from an Indian regulator allows conducting an adaptive…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-19 02:31:152020-10-19 02:31:16Dr. Reddy’s, RDIF secure DCGI’s approval for Sputnik V vaccine trial in India

Sanofi, Translate Bio mRNA Covid-19 vaccine candidate induced high antibody levels in preclinical studies

0 Comments
/
10/16/2020
Preclinical evaluation of MRT5500, importantly, demonstrated…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-16 04:01:352020-10-16 04:01:36Sanofi, Translate Bio mRNA Covid-19 vaccine candidate induced high antibody levels in preclinical studies

FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL

0 Comments
/
10/16/2020
The approval is based on results from the Phase 3 KEYNOTE-204…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-16 03:01:422020-10-16 03:01:42FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL

ImmunityBio gets FDA authorisation to begin trial of novel Covid-19 vaccine candidate

0 Comments
/
10/16/2020
The human adenovirus (hAd5) vector vaccine candidate has been…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-16 03:01:422020-10-16 03:01:43ImmunityBio gets FDA authorisation to begin trial of novel Covid-19 vaccine candidate

Eli Lilly to buy biotechnology firm Disarm Therapeutics

0 Comments
/
10/16/2020
The deal also allows Disarm equity-holders to secure up to $1.225bn…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-16 00:31:122020-10-16 00:31:12Eli Lilly to buy biotechnology firm Disarm Therapeutics

Moderna secures eligibility for submission of MAA of mRNA-1273 to EMA

0 Comments
/
10/15/2020
Confirmation of eligibility was given in response to the submission…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-15 04:01:172020-10-15 04:01:17Moderna secures eligibility for submission of MAA of mRNA-1273 to EMA

Y-mAbs announces FDA clearance of IND for its Lutetium-177 labelled omburtamab antibody

0 Comments
/
10/15/2020
Medulloblastomas are invasive, rapidly growing tumors that, unlike…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-15 04:01:162020-10-15 04:01:16Y-mAbs announces FDA clearance of IND for its Lutetium-177 labelled omburtamab antibody

Regeneron’s Inmazeb gets FDA approval for Ebola treatment

0 Comments
/
10/15/2020
Inmazeb, which was previously called REGN-EB3, is now the first…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-15 00:31:242020-10-15 00:31:25Regeneron’s Inmazeb gets FDA approval for Ebola treatment

World Bank sanctions $12bn to help countries access Covid-19 vaccines

0 Comments
/
10/14/2020
Approved by the institution’s board of executive directors,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-14 00:31:072020-10-14 00:31:08World Bank sanctions $12bn to help countries access Covid-19 vaccines

Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer

0 Comments
/
10/13/2020
The cohort is evaluating the antibody-drug conjugate PADCEV (enfortumab…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-13 04:01:122020-10-13 04:01:12Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer

HitGen to acquire fragment and structure-based biotech company Vernalis

0 Comments
/
10/13/2020
The acquisition is for the entire issued share capital of Vernalis…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-13 02:01:362020-10-13 02:01:36HitGen to acquire fragment and structure-based biotech company Vernalis

J&J halts Covid-19 vaccine trials after unexplained illness in participant

0 Comments
/
10/13/2020
The halted trails also include the large-scale, pivotal and multi-country…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-13 02:01:362020-10-13 02:01:37J&J halts Covid-19 vaccine trials after unexplained illness in participant

Rigel enrols first patients in phase 2 Covid-19 trial of fostamatinib

0 Comments
/
10/12/2020
The National Heart, Lung, and Blood Institute (NHLBI), part of…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-12 06:32:092020-10-12 06:32:10Rigel enrols first patients in phase 2 Covid-19 trial of fostamatinib

BMS presents positive data from phase 3 True North Trial of Zeposia in UC

0 Comments
/
10/12/2020
True North met both primary endpoints, demonstrating highly statistically…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-12 04:31:222020-10-12 04:31:23BMS presents positive data from phase 3 True North Trial of Zeposia in UC

Gannex received US IND approval for its NASH Drug Candidate ASC42

0 Comments
/
10/12/2020
ASC42 is an in-house developed novel non-steroidal, selective,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-10-12 04:01:362020-10-12 04:01:36Gannex received US IND approval for its NASH Drug Candidate ASC42
PreviousNext

  • Thorough Network

  • Deep Knowledge

  • Comprehensive Process

  • Ethical Approach

  • Confidentiality

  • Assessment Capacity

99%

Percentage of successful project completion

85%

Of placed executives remain with the client company 3 or more years

  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

Archives

Follow CAPTIS



CAPTIS
Followon TwitterSubscribeto RSS Feed

We Recommend

Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News

CAPTIS Newsletter

Call CAPTIS

United States Offices
1 (800) 445-1839

(United States & Canada Toll Free)

Europe & International
+41 22 518 2100

© CAPTIS - Executive Search - 2017 - [email protected]
  • LinkedIn
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Youtube
  • Rss
  • Events
  • For Healthcare Executives
  • Legal & Privacy Notes, GDPR & Cookies Policy
  • Client Area
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy
Scroll to top